Bristol/AstraZeneca Initiate Phase III Studies Of SGLT-2 Inhibitor Dapagliflozin
This article was originally published in The Pink Sheet Daily
Drug is on track to become first-in-class treatment for type 2 diabetes.
You may also be interested in...
Safety study responding to FDA’s “approvable” letter for the type 2 diabetes therapy will take months, not weeks; firm also faces delay for oncologic Tasigna.
Companies report Phase IIa data evaluating the sodium-glucose transporter 2 inhibitor at American Diabetes Association meeting.
Analysts indicate approval of the type 2 diabetes therapy could be delayed for a year or more.